Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA

References

• Ingimarsdottir IJ, Rusch E, Engholm G, et al. Quality assessment of prostate cancer reports to the Danish Cancer Registry. Acta Oncol. 2016;55:24–29.
   PubMed Web of Science ®Google Scholar
• de Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol. 2014;15:23–34.
   PubMed Web of Science ®Google Scholar
• Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713–2719.
   PubMed Web of Science ®Google Scholar
• Rider JR, Sandin F, Andren O, et al. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol. 2013;63:88–96.
   PubMed Web of Science ®Google Scholar
• Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272–277.
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, Bertaccini A, Bono AV, et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract. 2003;57:187–194.
   PubMed Web of Science ®Google Scholar
• Glass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164–169.
   PubMed Web of Science ®Google Scholar
• Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol. 2012;23:1325–1334.
   PubMed Web of Science ®Google Scholar
• Finnish Cancer Registry, Cancer Statistics of Finland. [cited 2016 Nov 8]. Available from: http://tilastot.syoparekisteri.fi/?_inputs_&in.subset.area=%22-1L%22&in.subset.sex=%220L%22&in.subset.sites=%2232L%22&language=%22fi%22&submit=2&tabset_panel=%221%22&tabu=%221%22&value_theme=%22theme_inc%22&value_type=%22inc.rate_finland_2014%22.
   Google Scholar
• Lu-Yao GL, Potosky AL, Albertsen PC, et al. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996;88:166–173.
   PubMedGoogle Scholar
• Ritch CR, Graves AJ, Keegan KA, et al. Increasing use of observation among men at low risk for prostate cancer mortality. J Urol. 2015;193:801–806.
   PubMed Web of Science ®Google Scholar
• Loeb S, Folkvaljon Y, Makarov DV, et al. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol. 2015;67:233–238.
   PubMed Web of Science ®Google Scholar
• Houterman S, Janssen-Heijnen ML, Hendrikx AJ, et al. Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study. Crit Rev Oncol Hematol. 2006;58:60–67.
   PubMed Web of Science ®Google Scholar
• Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941–949.
   PubMed Web of Science ®Google Scholar
• Touijer KA, Mazzola CR, Sjoberg DD, et al. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. 2014;65:20–25.
   PubMed Web of Science ®Google Scholar
• Breslow NE, Day NE. Statistical methods in cancer research. Volume II – the design and analysis of cohort studies. IARC Sci Publ 1987;(82:):1–406.
   Google Scholar
• Seppa K, Hakulinen T, Laara E, Pitkaniemi J. Comparing net survival estimators of cancer patients. Stat Med 2016;35:1866–1879.
   PubMed Web of Science ®Google Scholar
• van Hemelrijck M, Folkvaljon Y, Adolfsson J, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int 2016;117:507–514.
   PubMed Web of Science ®Google Scholar
• Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374–383.
   PubMedGoogle Scholar
• Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009;101:1325–1329.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Shen X, Kumar P. Trade-off between treatment of early prostate cancer and incidence of advanced prostate cancer in the prostate screening era. J Urol. 2016;195:1397–1402.
   PubMed Web of Science ®Google Scholar
• Jonsson H, Holmstrom B, Duffy SW, et al. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer. 2011;129:1881–1888.
   PubMed Web of Science ®Google Scholar
• Kilpelainen TP, Tammela TL, Malila N, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst. 2013;105:719–725.
   PubMedGoogle Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–2035.
   PubMed Web of Science ®Google Scholar
• Stattin P, Carlsson S, Holmström B, et al. Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst. 2014;106:dju007.
   PubMedGoogle Scholar
• Bray F, Lortet-Tieulent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46:3040–3052.
   PubMed Web of Science ®Google Scholar
• Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165–1174.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Higano CS, Shore ND, et al. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537–1547.
   PubMed Web of Science ®Google Scholar
• Pinsky PF, Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007;165:874–881.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.
   PubMed Web of Science ®Google Scholar